Brought to you by 
Fresenius to market Cypress's Prosorba for RA
24 Sep 1999
Executive Summary
Fresenius (dialysis) has licensed rights to distribute Cypress's Prosorba column, the first non-drug treatment for rheumatoid arthritis, in the US, Europe, Latin America, and subject to certain conditions, in Japan and other Asian countries.
Deal Industry
- Biotechnology
- Medical Devices
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fresenius to market Cypress's Prosorba for RA
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice